Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Olson

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Current Opinion in Pharmacology|September 27, 2002
HIV entry inhibitors in clinical developmentBryan M O'Hara, William C Olson
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
Antibody-drug conjugates targeting prostate-specific membrane antigenWilliam C Olson, Robert J Israel
Current Opinion in HIV and AIDS|April 3, 2009
CCR5 monoclonal antibodies for HIV-1 therapyWilliam C Olson, Jeffrey M Jacobson
Reviews on Recent Clinical Trials|May 14, 2008
Clinical trials of cancer therapies targeting prostate-specific membrane antigenWilliam C Olson, Warren D W Heston, Ayyappan K Rajasekaran
Molecular Cancer Therapeutics|July 14, 2011
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigenXinning Wang, Dangshe Ma, William C Olson, et al.
Journal of Virology|January 15, 2005
Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1Xavier Carnec, Lan Quan, William C Olson, et al.
Nature Reviews. Drug Discovery|July 15, 2017
Opportunities for therapeutic antibodies directed at G-protein-coupled receptorsCatherine J Hutchings, Markus Koglin, William C Olson, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2006
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Jose D Murga, Michael Franti, Daniel C Pevear, et al.
AIDS Research and Human Retroviruses|October 31, 2003
A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapiesSeth H Pincus, Hua Fang, Royce A Wilkinson, et al.
Journal of the American Chemical Society|August 5, 2004
Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalencyVadim Y Dudkin, Marianna Orlova, Xudong Geng, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Current Opinion in Pharmacology|September 27, 2002
HIV entry inhibitors in clinical developmentBryan M O'Hara, William C Olson
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
Antibody-drug conjugates targeting prostate-specific membrane antigenWilliam C Olson, Robert J Israel
Current Opinion in HIV and AIDS|April 3, 2009
CCR5 monoclonal antibodies for HIV-1 therapyWilliam C Olson, Jeffrey M Jacobson
Reviews on Recent Clinical Trials|May 14, 2008
Clinical trials of cancer therapies targeting prostate-specific membrane antigenWilliam C Olson, Warren D W Heston, Ayyappan K Rajasekaran
Molecular Cancer Therapeutics|July 14, 2011
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigenXinning Wang, Dangshe Ma, William C Olson, et al.
Journal of Virology|January 15, 2005
Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1Xavier Carnec, Lan Quan, William C Olson, et al.
Nature Reviews. Drug Discovery|July 15, 2017
Opportunities for therapeutic antibodies directed at G-protein-coupled receptorsCatherine J Hutchings, Markus Koglin, William C Olson, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2006
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1Jose D Murga, Michael Franti, Daniel C Pevear, et al.
AIDS Research and Human Retroviruses|October 31, 2003
A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapiesSeth H Pincus, Hua Fang, Royce A Wilkinson, et al.
Journal of the American Chemical Society|August 5, 2004
Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalencyVadim Y Dudkin, Marianna Orlova, Xudong Geng, et al.
Pageof 8